News Releases

Keyword Search

Oct-05-2021
Oncternal Therapeutics Announced Pre-Clinical Data from ONCT-534, an Androgen Receptor N-Terminal-Domain-Binding Small Molecule Degrader, Was Accepted for Virtual Poster Presentation at AACR-NCI-EORTC Virtual International Conference on Molecular Targets
Oct-01-2021
Oncternal Therapeutics Reports Granting of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Sep-20-2021
Oncternal Therapeutics and Celularity Enter into Research Collaboration to Evaluate Targeted Placental-Derived Cellular Therapies
Sep-09-2021
Oncternal Therapeutics to Participate in September Investor Conferences
Sep-01-2021
Oncternal Therapeutics Rounds Out Leadership Team with Appointment of Steven Hamburger, Ph.D. as Senior Vice President, Regulatory Affairs and Quality Assurance
Aug-05-2021
Oncternal Provides Business Update and Announces Second Quarter 2021 Financial Results
Aug-02-2021
Oncternal Therapeutics Reports Granting of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Aug-02-2021
Oncternal Therapeutics to Participate in the BTIG Virtual Biotechnology Conference
Jul-29-2021
Oncternal Therapeutics to Provide Business Update and Report Second Quarter 2021 Financial Results
Jul-01-2021
Oncternal Therapeutics Appoints Pablo Urbaneja as Sr. Vice President, Corporate Development